[PDF] Top 20 Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
Has 10000 "Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial" found on our website. Below are the top 20 most common "Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial".
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
... the phase II study, was 41% (95% CI 26% to 56%) for all patients and 50% (95% CI 31% to 69%) for patients with good PS, hence much higher than expected from ... Voir le document complet
6
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer
... Two phase II studies have shown a median survival of ...months and a clinical benefit in patients undergoing treatment with the combination gemcitabine plus ... Voir le document complet
6
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
... Most patients with newly diagnosed carcinoma of the esophagus present with locally advanced ...locoregional and distant failure, there has been much interest in combining ... Voir le document complet
7
Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study
... RESULTS Patients underwent surgery in eight different ...6 patients developed intra-abdominal ...of Oxaliplatin was reduced from 460mg/M2 to ...9 patients. The clinical trial was then ... Voir le document complet
19
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
... in a treatment duration of 18 weeks or ...months for arm A and 7.2 months for arm B suggesting a short response duration off treatment in most of these ...stability and ... Voir le document complet
5
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
... data and materials Not applicable. Ethics approval and consent to participate This trial is carried out in accordance with Public Health Act 2004 –806 of 9 August 2004 concerning biomedical ... Voir le document complet
12
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer : Treatment outcome outside clinical trials = Simultane neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom : Therapieergebnisse außerhalb klinischer Studien
... 22 and 29). Radiotherapy Megavoltage equipment was used with 6/10/18 ...MV. Patients were immobilized in the prone position using a belly ...All patients received individual ... Voir le document complet
6
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
... in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 ...thresholds and are promising for the experimental ...in a phase III ... Voir le document complet
8
Feasibility of capecitabine and oxaliplatin combination (XELOX) chemotherapy without central venous access device in patients with stage III colorectal cancer
... regimen, capecitabine is administered orally, with intravenous administration of ...that oxaliplatin is classified as an irritating cytostatic regimen, 12 its administration through a ... Voir le document complet
11
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
... normal. Patients had to be able to understand the EORTC quality-of-life questionnaire C-30, which had previously been validated in several language-cultural groups across ...Europe. Patients were not ... Voir le document complet
11
A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance
... Patients and methods Patient selection Patients were eligible if they were at least 18 years of age with histologically proven advanced solid ...mitomycin-C and nitrosourea) ... Voir le document complet
6
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
... EGFR, gemcitabine, HER2, monoclonal antibodies, pancreatic carcinoma introduction Pancreatic cancer is the fourth leading cause of cancer death in both men and ...most pancreatic ... Voir le document complet
6
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
... Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma North Central Cancer Treatment Group results. Kyritsis AP, Yung WK[r] ... Voir le document complet
8
192ir Low Dose Rate Brachytherapy for Boosting Locally Advanced Prostate Cancers after External Beam Radiotherapy: A Phase Ii Trial
... Eight patients (4%) presented late grade 2 rectal complications but no grade 3–5 complication was ...201 patients with locally advanced prostate ...prospectively and consecutively ... Voir le document complet
6
A phase I/II clinical trial of autologous myoblast transplantation in facioscapulohumeral muscular dystrophy
... feasible and clinically well tolerated by all patients but ...response and slight decrease in fatigue in the 3rd ...(myoblasts) and of the modality (dense multisite injections) may have ... Voir le document complet
2
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
... is a major cause of morbidity and mortality globally [ 1 ...of patients will develop metastatic disease, and while some patients with technically resectable liver (or lung) ... Voir le document complet
8
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
... ATLAS patients whose tumor tissue samples could be assessed for genomic LOH, 40% had HRD- positive ...ATLAS patients was consistent with the data from TCGA-BLCA samples, suggesting that ... Voir le document complet
14
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
... immunohisto-chemistry for assessing the benefit from gemcitabine adjuvant chemotherapy in patients with early stage pancreatic ...in gemcitabine metabolism, such as dCK, cytidine ... Voir le document complet
8
Phase I-II Trial of Foscarnet for Prevention of Cytomegalovirus Infection in Autologous and Allogeneic Marrow Transplant Recipients
... Exclusion criteria were age < 12 years, a known allergy to foscarnet, ongoing treatment with acyclovir or ganciclovir, graft-versus-host disease (GVHD) pro- phylactic regimen other th[r] ... Voir le document complet
7
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial
... The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial.. Goldhirsch for the Swiss Group for Clinical Cancer Res[r] ... Voir le document complet
8
Sujets connexes